SSEP N20与P25波幅预测心脏骤停后神经功能预后
该单中心前瞻性研究纳入82例心脏骤停后72小时仍昏迷且至少记录一次SSEP的患者,自动测量N20-b与N20-P25波幅(µV),并结合肌阵挛状态、2天和3天神经元特异性烯醇化酶水平及EEG模式,评估SSEP对3个月(主要终点)和6个月(次要终点)神经功能预后(CPC1-2为良好)的预测价值。3个月时78%患者预后不良(CPC3-5)。预后不良组N20-b中位波幅0.93 [0-2.05]µV vs 预后良好组1.56 [1.24-2.75]µV(p<0.0001);N20-P25中位波幅预后不良组0.57 [0-1.43]µV vs 预后良好组2.64 [1.39-3.80]µV(p<0.0001)。N20-b>2 µV预测良好预后特异性73%、敏感性39%;N20-P25>3.2 µV特异性93%、敏感性30%;N20-b<0.88 µV与N20-P25<1 µV预测不良预后特异性分别为94%和93%,敏感性分别为50%和66%。「双侧缺失或低波幅SSEP」联合模式较「双侧缺失」单独预测不良预后的敏感性显著提高(58% vs 30%,p=0.002)。作者认为SSEP波幅在临床常规中需谨慎使用,应作为心脏骤停后多模态预后评估的一部分。
要点
- 心脏骤停后昏迷患者中,N20-b<0.88 µV预测不良预后(CPC3-5)特异性94%、敏感性50%;N20-P25<1 µV特异性93%、敏感性66%。
- N20-b>2 µV预测良好预后(CPC1-2)特异性73%、敏感性39%;N20-P25>3.2 µV特异性93%、敏感性30%。
- 「双侧缺失或低波幅SSEP」联合模式预测不良预后的敏感性58%,显著高于「双侧缺失」单独的30%(p=0.002)。
- 预后不良组与良好组的N20-b中位波幅分别为0.93 [0-2.05]µV vs 1.56 [1.24-2.75]µV(p<0.0001),N20-P25分别为0.57 [0-1.43]µV vs 2.64 [1.39-3.80]µV(p<0.0001)。
- 作者认为SSEP波幅在临床常规中需谨慎解读,应作为心脏骤停后多模态预后评估的一部分,而非单独使用。
适用人群与场景
- 纳入2019年11月至2021年7月单中心三级心脏中心所有心脏骤停后72小时仍昏迷且至少记录一次SSEP的患者。
诊断标准与关键阈值
- 神经功能预后以3个月(主要终点)和6个月(次要终点)最佳CPC评分评估,CPC1或2定义为良好预后,CPC3-5为不良预后。
- SSEP记录中位时间为心脏骤停后3(2-4)天,模式分为「双侧缺失」19例、「单侧存在」4例、「双侧存在」59例。
研究设计与关键结果
- 单中心前瞻性研究纳入82例心脏骤停后72小时仍昏迷且至少记录一次SSEP的患者,3个月时78%预后不良(CPC3-5)。
- 预后不良组 vs 良好组的N20-b中位波幅为0.93 [0-2.05]µV vs 1.56 [1.24-2.75]µV(p<0.0001),N20-P25中位波幅为0.57 [0-1.43]µV vs 2.64 [1.39-3.80]µV(p<0.0001)。
- N20-b>2 µV预测良好预后特异性73%、敏感性39%;N20-P25>3.2 µV预测良好预后特异性93%、敏感性30%。
- N20-b<0.88 µV预测不良预后特异性94%、敏感性50%;N20-P25<1 µV预测不良预后特异性93%、敏感性66%。
- 「双侧缺失或低波幅SSEP」联合模式预测不良预后的敏感性58%,显著高于「双侧缺失」SSEP单独的30%(p=0.002)。
证据类型、等级与局限
- 证据类型:单中心前瞻性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,SSEP波幅在临床常规中需谨慎解读,应作为心脏骤停后多模态预后评估的一部分,而非单独用于预后判断。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: To assess in comatose patients after cardiac arrest (CA) if amplitudes of two somatosensory evoked potentials (SSEP) responses, namely, N20-baseline (N20-b) and N20-P25, are predictive of neurological outcome.
METHODS: Monocentric prospective study in a tertiary cardiac center between Nov 2019 and July-2021. All patients comatose at 72 h after CA with at least one SSEP recorded were included. The N20-b and N20-P25 amplitudes were automatically measured in microvolts (µV), along with other recommended prognostic markers (status myoclonus, neuron-specific enolase levels at 2 and 3 days, and EEG pattern). We assessed the predictive value of SSEP for neurologic outcome using the best Cerebral Performance Categories (CPC1 or 2 as good outcome) at 3 months (main endpoint) and 6 months (secondary endpoint). Specificity and sensitivity of different thresholds of SSEP amplitudes, alone or in combination with other prognostic markers, were calculated.
RESULTS: Among 82 patients, a poor outcome (CPC 3-5) was observed in 78% of patients at 3 months. The median time to SSEP recording was 3(2-4) days after CA, with a pattern "bilaterally absent" in 19 patients, "unilaterally present" in 4, and "bilaterally present" in 59 patients. The median N20-b amplitudes were different between patients with poor and good outcomes, i.e., 0.93 [0-2.05]µV vs. 1.56 [1.24-2.75]µV, respectively (p < 0.0001), as the median N20-P25 amplitudes (0.57 [0-1.43]µV in poor outcome vs. 2.64 [1.39-3.80]µV in good outcome patients p < 0.0001). An N20-b > 2 µV predicted good outcome with a specificity of 73% and a moderate sensitivity of 39%, although an N20-P25 > 3.2 µV was 93% specific and only 30% sensitive. A low voltage N20-b < 0.88 µV and N20-P25 < 1 µV predicted poor outcome with a high specificity (sp = 94% and 93%, respectively) and a moderate sensitivity (se = 50% and 66%). Association of "bilaterally absent or low voltage SSEP" patterns increased the sensitivity significantly as compared to "bilaterally absent" SSEP alone (se = 58 vs. 30%, p = 0.002) for prediction of poor outcome.
CONCLUSION: In comatose patient after CA, both N20-b and N20-P25 amplitudes could predict both good and poor outcomes with high specificity but low to moderate sensitivity. Our results suggest that caution is needed regarding SSEP amplitudes in clinical routine, and that these indicators should be used in a multimodal approach for prognostication after cardiac arrest.
参考来源
- Benghanem S, Nguyen LS, Gavaret M, et al. SSEP N20 and P25 amplitudes predict poor and good neurologic outcomes after cardiac arrest. Ann Intensive Care. 2022. PMID: 35290522. doi:10.1186/s13613-022-00999-6
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。